US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

The trial, which was funded by the drugs’ maker Eli Lilly, found that most patients on the medication ... Ms. Behlke ...

Patients treated with Wegovy had a higher risk of hip and pelvic fractures ... GIPR is involved in insulin release and glycemic control. Rival drugs from Eli Lilly and Viking Therapeutics also target ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

25 mg starter dose of semaglutide-based obesity med Wegovy is now available in the U.S. Last month, the FDA removed Eli Lilly ...

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...